



COPY

ATTORNEY DOCKET 8325-2008 DATE 10/24/03

1. IDS;
2. PTO/SB/08A;
3. cited references B1-16, C1-5;
4. PCT Search Reports PCT/GB00/02080 & PCT/GB00/02071;
5. Transmittal

PAPER: _____

INVENTOR: Choo et al.

SERIAL NO.: 09/996,484

FILING DATE: 11/28/01

RECEIVED BY THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET 8325-2008 DATE 10/24/03

1. IDS;
2. PTO/SB/08A;
3. cited references B1-16, C1-5;
4. PCT Search Reports PCT/GB00/02080 & PCT/GB00/02071;
5. Transmittal

PAPER: _____

INVENTOR: Choo et al.

SERIAL NO.: 09/996,484

FILING DATE: 11/28/01



RECEIVED BY THE UNITED STATES PATENT AND TRADEMARK OFFICE




Attorney Docket No. 8325-2008 (G8-US1)

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 10/24/03.

By:


Yang Tang

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of CHOO et al.

Serial No.: 09/996,484

Examiner: Unassigned

Confirmation No.: 2713

Art Unit: 1645

Filed: November 28, 2001

For: MOLECULAR SWITCHES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08A for the above-identified patent application.

- ☒ [X] In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.
- ☐ [] In accordance with 37 C.F.R. §1.97(c), also enclosed is:
 - ☐ [] the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p); or
 - ☐ [] a statement as specified in 37 C.F.R. §1.97(e).
- ☐ [] In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. § 1.97(e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.
- ☐ [] Check No. ___ in the amount of \$___ for the total fee is attached.

☒ [X] A return receipt postcard is also enclosed.

☐ [] Please charge \$_____ to Deposit Account No. 18-1648 for the total fee.
This paper is being submitted in duplicate.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 18-1648.

Dated: Oct 22/03

Respectfully submitted,

Robins & Pasternak LLP
1731 Embarcadero Road, Suite 230
Palo Alto, CA 94303
Tel: (650) 493-3400
Fax: (650) 493-3440

By:

Dahna S. Pasternak
Dahna S. Pasternak
Reg. No. 41,411

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Sheet	1	of	2	Application Number	09/996,484
				Filing Date	November 28, 2001
				First Named Inventor	CHOO
				Group Art Unit	1645
				Examiner Name	Unassigned
				Attorney Docket Number	8325-2008 (G8-US1)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B1	WO	92/00388	A1	The Regents of the University of California	01-09-1992	
	B2	WO	93/23431	A1	Baylor College of Medicine	11-25-1993	
	B3	WO	94/29442	A2	BASF Aktiengesellschaft	12-22-1994	
	B4	WO	95/20652	A1	Altmann, Herbert	08-03-1995	
	B5	WO	96/01313	A1	Bujard, Hermann	01-18-1996	
	B6	WO	96/06166	A1	Medical Research Council	02-29-1996	
	B7	WO	96/20951	A1	Massachusetts Institute of Technology	07-11-1996	
	B8	WO	96/40892	A1	BASF AG	12-19-1996	
	B9	WO	96/41865	A1	Ariad Gene Therapeutics, Inc.	12-27-1996	
	B10	WO	97/10337	A1	Baylor College of Medicine	03-20-1997	
	B11	WO	97/31113	A1	Ariad Pharmaceuticals, Inc.	08-28-1997	
	B12	WO	98/25947	A1	Bristol-Myers Squibb Company	06-18-1998	
	B13	WO	98/53057	A1	Medical Research Council	11-26-1998	
	B14	WO	99/01549	A1	BASF Aktiengesellschaft	01-14-1999	
	B15	WO	99/10510	A2	Ariad Gene Therapeutics, Inc.	03-04-1999	
	B16	WO	00/73434	A1	Gendaq Limited	12-07-2000	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.



Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/996,484
				Filing Date	November 28, 2001
				First Named Inventor	CHOO
				Group Art Unit	1645
Examiner Name	Unassigned				
Sheet	2	of	2	Attorney Docket Number	8325-2008 (G8-US1)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Dickinson et al., "Inhibition of RNA Polymerase II Transcription in Human Cells by Synthetic DNA-Binding Ligands," <i>PNAS</i> <u>95</u> (22):12890-12895 (1998)	
	C2	Dickinson et al., "Inhibition of Ets-1 DNA Binding and Ternary complex Formation Between Ets-1, NF-KappaB, and DNA by a Designed DNA-Binding Ligand," <i>Journal of Biological Chemistry</i> <u>274</u> (18):12765-12773 (1999)	
	C3	Gatz et al., "Stringent Repression and Homogenous De-Repression by Tetracycline of a Modified CaMV 35S Promoter in Intact Transgenic Tobacco Plants," <i>Plant Journal</i> <u>2</u> (3):397-404 (1992)	
	C4	Gottesfed et al., "Regulation of Gene Expression by Small Molecules," <i>Nature</i> <u>387</u> (6629):202-205 (1997)	
	C5	Weinmann et al., "Chimeric Transactivator Allows Tetracycline-Responsive Gene Expression in Whole Plants," <i>Plant Journal</i> <u>5</u> (4):559-569 (1994)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.